HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HLN
Haleon plc
There isn't enough reported data to score HLN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Stable |
HLN's profitability is currently strong, and its balance sheet is stable. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HLN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $9.09 | — |
| Cheap | 20x | $4.96 | -45% |
| Fair | 26x | $6.41 | -30% |
| Expensive | 32x | $7.99 | -12% |
Historical ranges are pointers, not guarantees.
HLN's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HLN Forward outlook
There aren't enough analyst estimates for HLN to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.25 | +19% |
| Q4 2024 | $0.21 | +40% |
| Q4 2023 | $0.15 | 0% |
HLN has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $14.7B | +99% |
| Q4 2024 | $7.4B | -0.4% |
| Q2 2024 | $7.6B | -0.8% |
| Q4 2023 | $7.4B | -49% |
| Q4 2022 | $14.4B | +336% |
HLN has the edge over HIMS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 22% | +2 points |
| Q4 2024 | 19% | +2.2 points |
| Q2 2024 | 20% | -0.1 points |
| Q4 2023 | 15% | +0.7 points |
| Q2 2023 | 20% | N/A |
| Q4 2022 | 17% | N/A |
| Q4 2021 | 20% | N/A |
| Q2 2021 | 15% | N/A |
HLN's operating margin was 22% last quarter, up 2 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
HLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $3.1B | +79% |
| Q4 2024 | $1.7B | +4.5% |
| Q2 2024 | $1B | +21% |
| Q4 2023 | $1.6B | -30% |
| Q4 2022 | $2.3B | +$2.3B |
HLN's free cash flow has been positive every quarter since mid-2021: $7.5B over the past year, up 135% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HLN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -149M shares |
| 1 year | -2.6% | -238M shares |
HLN has 9B diluted shares, down 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $200.9M |
| Q4 2024 | $267.4M |
| Q2 2024 | $421.7M |
| Q4 2021 | — |
| Q2 2021 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over HLN on leverage, with a lower net debt burden relative to earnings.
HLN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.6x | Moderate |
| Q4 2024 | 3.1x | Elevated |
| Q2 2024 | 3.6x | Elevated |
| Q4 2023 | 3.7x | Elevated |
| Q4 2022 | 4.6x | High |
HLN's net debt is about 2.6 years of its operating earnings (EBITDA), down from 4.6 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.9 | Neutral |
HLN's weekly RSI is 46 (neutral) and its Stochastic is 29 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HLN PE vs Healthcare Sector
| Metric | HLN | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 6 | 45 | 39 pts below |
HLN is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.33 | 2.6% below |
| 20 week MA | $9.60 | 5.3% below |
| 50 week MA | $9.75 | 6.8% below |
| 100 week MA | $9.83 | 7.5% below |
| 200 week MA | $9.25 | 1.7% below |
HLN is in a downtrend: it's below all five of its weekly moving averages, and 1.7% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $7.41 | $8.00 | +8% |
| 2023 | $8.00 | $8.23 | +2.9% |
| 2024 | $8.23 | $9.64 | +17% |
| 2025 | $9.64 | $10.1 | +5.1% |
| 2026 YTD | $10.1 | $9.09 | -10% |
HLN has the edge over HIMS on returns for 2026, with the stronger performance.